(Q34073541)

30 July 2017

title

Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine (English)

1 reference

30 July 2017

0 references

0 references

Annelies Wilder-Smith

2

Annelies Wilder-Smith

0 references

David Shu-cheong Hui

David S Hui

6

0 references

Yuen Kwok-yung

Kwok-yung Yuen

7

0 references

Otfried Kistner

13

Otfried Kistner

1 reference

30 July 2017

8

Sandor Fritsch

1 reference

30 July 2017

14

Hartmut J Ehrlich

1 reference

30 July 2017

4

P Noel Barrett

1 reference

Paul Anantharajah Tambyah

30 July 2017

1

Paul A Tambyah

1 reference

30 July 2017

Borislava G Pavlova

3

1 reference

30 July 2017

Helen M L Oh

5

1 reference

30 July 2017

Gerald Aichinger

9

1 reference

30 July 2017

Alexandra Loew-Baselli

10

1 reference

30 July 2017

Maikel van der Velden

11

1 reference

30 July 2017

Friedrich Maritsch

12

1 reference

30 July 2017

language of work or name

English

0 references

publication date

12 November 2011

1 reference

30 July 2017

1 reference

30 July 2017

volume

30

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

329-335

1 reference

Update on avian influenza A (H5N1) virus infection in humans

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Characterization of avian influenza viruses A (H5N1) from wild birds, Hong Kong, 2004-2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Evolution and adaptation of H5N1 influenza virus in avian and human hosts in Indonesia and Vietnam.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Development of a mammalian cell (Vero) derived candidate influenza virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Phylogenetic characterization of H5N1 avian influenza viruses isolated in Indonesia from 2003-2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Strategies for mitigating an influenza pandemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

T-cell recognition of influenza viral antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.10.088

10.1016/J.VACCINE.2011.10.088

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference